

Remarks

Applicants have cancelled claims 1- 48 without prejudice to their rights to pursue the subject matter of these claims in other applications. Applicants have added new claims 49 to 57 which redirect the subject matter of the invention towards a single selected gene to diagnose schizophrenia. As discussed with the Examiner, Applicants have thus shifted the current invention from the disease hypertension to schizophrenia. Applicants believe that the newly added claims are examinable without further restriction. Applicants thus respectfully request the Examiner accept the newly amended claims.

Applicant's have also amended the title of the pending application to more accurately reflect the subject matter of the newly amended claims.

Claims 49- 57 are pending. Support for the newly added claims is found through the specification and in the originally filed claims. In particular, support for the gene Charcot-Leyden crystal protein (CLC) is noted in Table Y under the RNA accession number NM_001828.3 with a p value of 0.021244492 and is described in Figure 26, Example 27. No new matter has been added.

In response to the Restriction Requirement dated August 30, 2006, Applicants elect **Group I** and have elected a single combination of "one or more" markers from the tables relevant to the detection of schizophrenia, namely Table 3Y.

As noted, the Applicant has elected the selection of the biomarker Charcot-Leyden crystal protein (CLC) which is found in Table 3Y.

A petition for extension of time is attached. However, should any fees be required to ensure consideration of this response, the Commissioner is authorized to charge Deposit Account 04-1105, Reference No. 204231/2055F.

Respectfully submitted,

Date: January 19, 2007

Amy De Cloux for
Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 29933

Amy De Cloux
54849

Edwards Angell Palmer & Dodge LLP
P.O. Box 55874
Boston, MA 02205
Tel: 617-239-0100